K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues
2004 (English)In: European Journal of Clinical Investigation, ISSN 0014-2972, E-ISSN 1365-2362, Vol. 34, no 2, p. 100-106Article in journal (Refereed) Published
Abstract [en]
Background: Colorectal cancer is a multistep process caused by genetic alterations in cellg rowth regulatory genes such as K-ras and B-raf. It has been assumed that mutations in the K-ras gene induce gastrin gene expression and that gastrin stimulates the growth of colorectal cancer in an autocrine fashion by coexpressing gastrin and cholecystokinin (CCK)2 receptors. The aim of this study was to examine a possible association of K-ras and B-raf gene mutations with gastrin and CCK2 receptor mRNA expression in human colon and rectum tumour biopsy specimens.
Methods: K-ras and B-rafgene mutations as well as gastrin and CCK2 receptor mRNA expression in 50 colon and 46 rectum biopsies, respectively, were determined using molecular biology methods.
Results: K-ras mutations occurred in 44% colon and 30% rectum and B-raf mutations in 16% colon and 4% rectum tumours, respectively. Gastrin mRNA was expressed in 64% colon and 61% rectum tumours, whereas CCK2 receptor mRNAs was expressed in 32% colon and 13% rectum tumours. K-ras or B-raf gene mutations and simultaneous gastrin mRNA expression was observed in 40% colon and 17% rectum tumours, respectively. Co-expression of gastrin and CCK2 receptor mRNA occurred in 20% colon and 9% rectal tumours.
Conclusions: The results do not support the hypothesis that K-ras and B-raf gene mutations have an impact on gastrin- and CCK-receptor mRNA expression in colorectal tumour tissues.
Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2004. Vol. 34, no 2, p. 100-106
Keywords [en]
B-rafgene mutation, CCK2 receptor mRNA, colorectal cancer, gastrin mRNA, gene expression, K-ras gene mutation
National Category
Medical Genetics and Genomics
Identifiers
URN: urn:nbn:se:oru:diva-113509DOI: 10.1111/j.1365-2362.2004.01296.xISI: 000188811400004PubMedID: 14764072Scopus ID: 2-s2.0-1342267520OAI: oai:DiVA.org:oru-113509DiVA, id: diva2:1856114
Funder
Swedish Cancer SocietyMedical Research Council of Southeast Sweden (FORSS)Region Östergötland2024-05-062024-05-062025-02-10Bibliographically approved